热门资讯> 正文

KalVista Pharmaceuticals超出第四季度预期

2026-03-25 19:09

KalVista Pharmaceuticals press release (KALV): Q4 GAAP EPS of -$2.03 may not be comparable to estimates.
Revenue of $49.08M beats by $16.79M.
As of December 31, 2025, the Company had cash, cash equivalents and marketable securities of approximately $300.2 million. We anticipate that cash, cash equivalents and marketable securities as of December 31, 2025, along with projected revenues associated with the sale of EKTERLY will fund the Company through profitability.

More on KalVista Pharmaceuticals

KalVista Pharmaceuticals: Has Potential But With Caveats
KalVista: Next Stage Of Growth For EKTERLY Lies With Pediatric Label Expansion
KalVista Pharmaceuticals Q4 2025 Earnings Preview
Quant snapshot: AAR, Noah Holdings lead strong buys as Blaize, Fractyl Health lag
Seeking Alpha’s Quant Rating on KalVista Pharmaceuticals

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。